Miraxion Approval Status
- FDA approved: No
- Brand name: Miraxion
- Generic name: eicosapentaenoic acid (EPA)
- Company: Amarin Corporation plc
- Treatment for: Huntington's Disease
Miraxion (eicosapentaenoic acid) is a phospholipid-based TLA2 inhibitor in development for the treatment of Huntington’s disease.
Development Status and FDA Approval Process for Miraxion
|Nov 19, 2007||Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.